Literature DB >> 23786967

Exome analysis reveals a Japanese family with spinocerebellar ataxia, autosomal recessive 1.

Yaeko Ichikawa1, Hiroyuki Ishiura, Jun Mitsui, Yuji Takahashi, Shunsuke Kobayashi, Hiroshi Takuma, Ichiro Kanazawa, Koichiro Doi, Jun Yoshimura, Shinichi Morishita, Jun Goto, Shoji Tsuji.   

Abstract

Spinocerebellar ataxia autosomal recessive 1 (SCAR1/AOA2) is clinically characterized by an early-onset progressive cerebellar ataxia with axonal neuropathy, ocular motor apraxia, and elevation of serum alpha-fetoprotein level. The disorder is caused by mutations in senataxin (SETX) gene. Here, we report a Japanese SCAR1/AOA2 family with a homozygous nonsense mutation (p.Q1441X) of SETX that was identified by exome sequencing. The family was previously reported as early-onset ataxia of undetermined cause. The present study emphasized the role of whole exome-sequence analysis to establish the molecular diagnosis of neurodegenerative disease presenting with diverse clinical presentations.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha-fetoprotein; Autosomal recessive 1; Exome analysis; Exon capture; Linkage analysis; Massively parallel sequencing; SETX; Spinocerebellar ataxia

Mesh:

Substances:

Year:  2013        PMID: 23786967     DOI: 10.1016/j.jns.2013.05.018

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  A Homozygous LAMA2 Mutation of c.818G>A Caused Partial Merosin Deficiency in a Japanese Patient.

Authors:  Akatsuki Kubota; Hiroyuki Ishiura; Jun Mitsui; Kaori Sakuishi; Atsushi Iwata; Tomotaka Yamamoto; Ichizo Nishino; Shoji Tsuji; Jun Shimizu
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

2.  A Novel SETX Mutation in a Taiwanese Patient with Autosomal Recessive Cerebellar Ataxia Detected by Targeted Next-Generation Sequencing, and a Literature Review.

Authors:  Ping-I Chiang; Ting-Wei Liao; Chiung-Mei Chen
Journal:  Brain Sci       Date:  2022-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.